Business
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
TORONTO and HOUSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference\n\n\n\n TORONTO and HOUSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage cancer immunotherapy company focused on the development of Superkines, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the H.C. Wainwright 27\n \n th\n \n Annual Global Investment Conference, taking place September 8-10, 2025, at the Lotte New York Palace Hotel in New York City.\n \n\n Details on the presentation are as follows:\n \n\n\n Date:\n \n Tuesday, September 9\n \n th\n \n , 2025\n \n\n Time:\n \n 2:30 PM – 3:00 PM (Eastern Standard Time)\n \n\n Location:\n \n Lotte New York Palace Hotel, Adams, 4\n \n th\n \n Floor\n \n\n Webcast Link:\n \n\n https://journey.ct.events/view/4f164af1-6cd9-41fe-a3dd-dc4f4bae7312\n \n\n\n Webcast and replay information for this event will also be available on the investor relations section of Medicenna’s website on the\n \n Events & Presentations\n \n page. The webcast will be available for 90 days.\n \n\n To schedule a one-on-one investor meeting with Dr. Fahar Merchant, please\n \n register\n \n for the conference or contact your H.C. Wainwright representative.\n \n\n\n About Medicenna Therapeutics\n \n\n\n Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Met...